¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Plant cell reports."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • memory T cell
    ±â¾ïT¼¼Æ÷
  • Merkel cell-neurite complex
    ¸Þ¸£Ä̼¼Æ÷½Å°æµ¹±âº¹ÇÕ, Ã˰¢¼¼Æ÷½Å°æµ¹±âº¹ÇÕü
  • mesangial cell
    Ç÷°ü»çÀ̼¼Æ÷, ¸Þ»êÁö¿ò¼¼Æ÷
  • mesenchymal cell
    Áß°£¿±¼¼Æ÷
  • mesothelial cell
    ÁßÇǼ¼Æ÷
  • microglial cell
    ¹Ì¼¼¾Æ±³¼¼Æ÷, ¼Ò±³¼¼Æ÷
  • natural killer cell leukemia
    ÀÚ¿¬»ìÇØ¼¼Æ÷¹éÇ÷º´
  • nerve cell
    ½Å°æ¼¼Æ÷
  • nerve cell body
    ½Å°æ¼¼Æ÷ü
  • nerve cell process
    ½Å°æ¼¼Æ÷µ¹±â
  • neural crest cell
    ½Å°æ´É¼±¼¼Æ÷
  • neuroendocrine cell
    ½Å°æ³»ºÐºñ¼¼Æ÷
  • neuroepithelial cell
    ½Å°æ»óÇǼ¼Æ÷
  • neuroglial cell
    ½Å°æ¾Æ±³¼¼Æ÷, ½Å°æ±³¼¼Æ÷
  • neurosecretory cell
    ½Å°æºÐºñ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • residential cell
    Á¤ÁÖ¼¼Æ÷
  • resting cell
    ÈÞÁö±â¼¼Æ÷, Á¤Áö¼¼Æ÷
  • reticular cell
    ±×¹°¼¼Æ÷
  • reticuloendothelial cell
    ±×¹°³»ÇǼ¼Æ÷, ¼¼¸Á³»ÇǼ¼Æ÷
  • reticulum cell
    (¢¡reticular cell) ±×¹°¼¼Æ÷
  • rod cell
    ¸·´ë¼¼Æ÷
  • rod shaped cell
    ¸·´ë¸ð¾ç¼¼Æ÷
  • round cell
    ¿øÇü¼¼Æ÷
  • satellite cell
    À§¼º¼¼Æ÷
  • scavenger cell
    û¼Ò¼¼Æ÷
  • Schwann¡¯s cell
    ½Å°æÁý¼¼Æ÷
  • sensitized cell
    ¹Î°¨¼¼Æ÷
  • sensory cell
    °¨°¢¼¼Æ÷
  • septal cell
    Á߰ݼ¼Æ÷
  • serous cell
    Àå¾×¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • immunity,cell-mediated
    ¼¼Æ÷¸Å°³¼º(á¬øàØÚË¿àõ)
  • immunocompetent cell
    ¸é¿ªÀû°Ý¼¼Æ÷.
  • immunodeficiency syndrome, cell mediated
    ¼¼Æ÷¸Å°³ ¸é¿ª°áÇÌ ÁõÈıº
  • immunologically committed cell
    ¸é¿ª°æÇè¼¼Æ÷(¡­ÌèúÐá¬øà).
  • immunologically competent cell
    ¸é¿ªÀû°Ý¼¼Æ÷(¡­îêÌ«á¬øà).
  • immunologically performing cell
    ¸é¿ª¼öÇ༼Æ÷(¡­âÄú¼á¬øà).
  • indeterminate cell
    ºÎÁ¤Çü(ÜôïÒû¡) ¼¼Æ÷(á¬øà)
  • indifferent cell
    ¹«°ü¼¼Æ÷.
  • indirect cell division
    °£Á¢¼¼Æ÷ºÐ¿­.
  • inducer T cell
    À¯µµ T ¼¼Æ÷
  • inner cell mass
    ³»¼¼Æ÷A(Ò®á¬øàÎÔ).
  • inner cell mass (embryoblast)
    ¼Ó¼¼Æ÷µ¢ÀÌ ¹èÀÚ¸ðü
  • inner cell mass embryoblast
    ¼Ó¼¼Æ÷µ¢ÀÌ ¹èÀÚ¸ðü
  • inner hair cell
    ³»À¯¸ð¼¼Æ÷(Ò®êáÙ¾á¬øà).
  • inner hair cell
    ¼ÓÅм¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • cell, null
    ¹«Ç¥Áö¼¼Æ÷
  • cell, permissive
    Áõ½ÄÇã¿ë¼¼Æ÷
  • cell, plaque-forming
    ÇöóÅ© Çü¼º¼¼Æ÷
  • cell, precursor
    Àü±¸¼¼Æ÷
  • cell, primed T
    ÃÊȸ°¨ÀÛ T¼¼Æ÷
  • cell, pyroninophilic blast
    ÇǷδѻê ģȭ¾Æ¼¼Æ÷
  • cell, resting
    ÈÞÁö±â¼¼Æ÷
  • cell, rosette forming
    ·ÎÁ¦Æ®Çü¼º¼¼Æ÷
  • cell, sensitized
    °¨ÀÛ¼¼Æ÷
  • cell, sensitized red blood
    °¨ÀÛÀûÇ÷±¸
  • cell, stem
    °£¼¼Æ÷, ±Ù°£¼¼Æ÷
  • cell, suppressor T
    ¾ïÁ¦T¼¼Æ÷
  • cell, tanned red
    ź´Ñ»êó¸® ÀûÇ÷±¸
  • cell, target
    Ç¥Àû¼¼Æ÷
  • cell, thymic epithelial
    °¡½¿»ù»óÇǼ¼Æ÷, Èä¼±»óÇǼ¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
PCV Packed Cell Volume
PRCA Pure Red Cell Aplasia
RBC Red Blood Cell (Count); ÀûÇ÷±¸, ÀûÇ÷±¸¼ö
RDW Red cell Distribution Width
SCC   1) Sude Chain-Cleavage Complex
  2) Squamous Cell Carcinoma
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
BREC bovine retinal endothelial cell
BCEC brain capillary endothelial cell
BMEC brain microvascular endothelial cell
BALC Bronchoalveolar lavage cell
CCH C cell hyperplasia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • prickle cell carcinoma
    ±Ø¼¼Æ÷ ¾Ï
  • prickle cell layer
    ±Ø¼¼Æ÷ Ãþ, À¯±Ø ¼¼Æ÷Ãþ, °¡½ÃÃþ, À¯±ØÃþ
    ÀÎÁ¢ ¼¼Æ÷¿Í ¼¼Æ÷°£±³¸¦ Çü¼ºÇϰí ÀÖ´Â °¢È­ ±¸°­ »óÇÇÀÇ ÇÑ ¼¼Æ÷Ãþ.
  • primary afferent cell body
    ÀÏÂ÷ ±¸½É¼º ¼¼Æ÷ü
  • primitive myoid cell
    ¿ø½Ã ±Ù ¼Ò¼¼Æ÷
  • primordial germ cell
    ¿ø½Ã »ý½Ä¼¼Æ÷, ½Ã¿ø »ý½Ä ¼¼Æ÷
    »ý¹°ÀÇ ¹ß»ý Ãʱ⿡ ÀåÂ÷ »ý½Ä¼Ò·Î ºÐÈ­µÉ ¿¹Á¤ÀÎ ¼¼Æ÷¿ª¿¡ À־ÀÇ ¹ÌºÐÈ­ »ý½Ä ¼¼Æ÷. ¿ø½Ã »ý½Ä ¼¼Æ÷, ½Ã¿ø¼º ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. ¹ß»ýÀÌ ÁøÇàµÇ¸é »ý½Ä¼ÒÀÇ ³­¿ø ¼¼Æ÷ ¶Ç´Â Á¤¿ø ¼¼Æ÷·Î ºÐÈ­ÇÑ´Ù. ½Ã¿ø »ý½Ä ¼¼Æ÷´Â ´Ù¸¥ Á¶Á÷ ¼¼Æ÷¿Í ±¸º°µÇ´Â ÇüÅÂÀû Ư¡À» °¡Áö¸ç, ¶ÇÇÑ »ý½Ä¼ÒÀÇ ¿¹Á¤¿ªº¸´Ù »ó´çÈ÷ ¶³¾îÁø ¹è¿ª¿¡ Á¸ÀçÇÑ´Ù. ÀÌ ¹è¿ª¿¡ Àå¾Ö¸¦ ÁÖ¸é »ý½Ä ¼¼Æ÷ÀÇ ºÐÈ­°¡ ÀϾÁö ¾Ê°Ô µÈ´Ù. ½Ã¿ø »ý½Ä ¼¼Æ÷´Â ü¼¼Æ÷¿Í´Â ¸í¹éÇÏ°Ô ±¸º°µÇ¸ç, ü¼¼Æ÷·ÎºÎÅÍ ½Ã¿ø »ý½Ä ¼¼Æ÷·Î ºÐÈ­µÇÁö ¾Ê´Â´Ù°í ÇÏ´Â »ý½ÄÁú ¿¬¼Ó¼³ÀÌ ÀϹÝÀûÀ¸·Î ÀÎÁ¤µÇ°í ÀÖ´Ù. ¿¹¸¦ µé¸é, ¸»È¸ÃæÀº 2°³ÀÇ ¿°»öü¸¦ °¡Áö´Âµ¥, À̰ÍÀº ÃÖÃÊÀÇ ³­ºÐÇÒ ¶§ºÎÅÍ »ý½Ä ¼¼Æ÷°è¿Í ü¼¼Æ÷°è·Î ³ª´©¾îÁø´Ù. »ý½Ä ¼¼Æ÷°è´Â 2°³ÀÇ ¿°»öü¸¦ °¡Áö°í ¿¬¼ÓÇÏÁö¸¸, ü¼¼Æ÷°è´Â ¿°»öü¿¡ Àý´ÜÀÌ ÀϾ¼­ ´Ù¼öÀÇ ¿°»öü ¼ö¸¦ °¡Áö´Â ¼¼Æ÷°è·Î ºÐÈ­ÇÑ´Ù.
  • principal cell
    ÁÖ ¼¼Æ÷
  • projection cell
    Åõ»ç ¼¼Æ÷
  • proliferating cell pool

    proliferating pleurisy (Áõ½Ä¼º È丷¿°

  • pyknotic endothelial cell
    ³óÃà ÇÙ ³»ÇÇ ¼¼Æ÷
  • pyramidal cell
    ÇǶó¹Ô ¼¼Æ÷, Ãßü ¼¼Æ÷, ÇǶó¹Ô ¸ð¾ç ¼¼Æ÷
    ºÎ¼öµÈ ¼¶À¯¿Í °°ÀÌ Ãßü ½Å°æ¿øÀ» ±¸¼ºÇϰí ÀÖ´Â ´ë³ú ÇÇÁúÀÇ Å©°í ´Ù±Ø¼ºÀÎ ÃßüÇü ½Å°æÀý ¼¼Æ÷ÀÇ Çϳª.
  • R-S cell
    ¸®µå-½ºÅÙ¹ö±× ¼¼Æ÷
    È£µåŲ½ºº´¿¡¼­ ³ªÅ¸³ª´Â ´ÙÇÙ °Å´ë ¼¼Æ÷.
  • red blood cell
    ÀûÇ÷±¸
    µ¿ÀǾî=erythrocyte. »ê¼Ò³ª ÀÌ»êȭź¼Ò¸¦ ¿î¹ÝÇÏ´Â Ç÷¾× ³»¿¡ Á¸ÀçÇÏ´Â Ç÷±¸.
  • red cell volume
    ÀûÇ÷±¸ ¿ëÀû
    ü³»ÀÇ ÃÑÀûÇ÷±¸ ¿ë·®À¸·Î¼­ ¹æ»ç´É µ¿À§¿ø¼Ò·Î ÃøÁ¤ÇÑ´Ù.
  • Reed-sternberg cell
    ¸®µå-½ºÅϹö±× ¼¼Æ÷
    Hodgkinº´¿¡ Ư¡ÀûÀÎ Ä¿´Ù¶õ ÀÌÇü Á¶Á÷±¸ÀÌ´Ù. ÀüÇüÀûÀÎ ¼¼Æ÷´Â ´ã¿°¼ºÀÇ È£»ê¼º ¼¼Æ÷ÁúÀ» °¡Áö¸ç, 1-2°³ÀÇ ´ëÇü ÇÙ ¶Ç´Â Áö³ªÄ¡°Ô ºÐ¿±ÇÑ ÇÙÀ» °®´Â´Ù. ±× ÇÙÀº º¯¿¬ºÎ¿¡´Â ¿°»öÁúÀÇ µ¢¾î¸®¿Í ºñÁ¤»óÀûÀ¸·Î ÇöÀúÇÑ È£»ê¼ºÀÇ ÇÙ¼Òü¸¦ °¡Áö°í ÀÖ´Ù. ÀÌÇÙ¼ºÀÇ °ÍÀº °¡²û °æ»óÇüÀ» ³ªÅ¸³½´Ù.
  • renal cell carcinoma
    ½Å ¼¼Æ÷ ¾ÏÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
CD4 cell T helper cells which are targets for HIV infection.
(09 Oct 1997)
CD4 cell count The most commonly used surrogate marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. The normal range for CD4 cell counts is 500 to 1500 per cubic millimetre of blood. CD4 count should be rechecked at least every six to twelve months if CD4s are greater than 500/mm3. If the count is lower, testing every three months is advised.
(09 Oct 1997)
virus-transformed cell A cell that has been genetically changed to a tumour cell, the change being subsequently tramsmitted to all descendent cell's; cell's transformed by oncornaviruses continue to produce virus in high concentration without being killed; DNA tumour virus-transformed cell's develop (along with other changes) tumour-associated antigens and rarely produce virus.
(05 Mar 2000)
CD8 cell <immunology> One type of T-lymphocyte which bears the CD8 molecular marker on its surface. Some CD8 cells recognise and kill cancerous cells and those infected by intracellular pathogens (some bacteria, viruses and mycoplasma). These cells are called cytotoxic T-lymphocytes (see).
(09 Oct 1997)
glomerulosa cell A cell of the zona glomerulosa of the adrenal cortex that is the source of aldosterone; the cell's are arranged in spherical or oval groups.
(05 Mar 2000)
cell <cell biology> An autonomous self replicating unit (in principle) that may constitute an organism (in the case of unicellular organisms) or be a sub unit of multicellular organisms in which individual cells may be more or less specialised differentiated) for particular functions.
The individual units from which tissues of the body are formed. All living organisms are composed of one or more cells.
(26 Mar 1998)
cell adhesion See: adhesins, cadherins, cell adhesion molecules (CAMs), contact sites A, DLVO theory, integrins, sorting out, uvomorulin and various specialised junctions (adherens junctions, desmosomes, focal adhesions, gap junction and zonula occludens).
(18 Nov 1997)
cell adhesion kinase <enzyme> From hela cells; involved in cell-cell interactions; genbank l20817
Registry number: EC 2.7.1.-
Synonym: cak protein
(26 Jun 1999)
cell adhesion molecule <molecular biology> Although this could mean any molecule involved in cellular adhesive phenomena, it has acquired a more restricted sense, namely a molecule on the surface of animal tissue cells, antibodies (or Fab fragments) against that specifically inhibit some form of intercellular adhesion.
Examples are Liver Cell Adhesion Molecule and Neural Cell Adhesion Molecule, both named from tissues in which first detected, although their occurrence is not in fact restricted to these.
Acronym: CAM
(26 Nov 1998)
cell adhesion molecules Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.
(12 Dec 1998)
cell adhesion molecules, neuronal Surface ligands that mediate cell-to-cell adhesion and function in the assembly and interconnection of the vertebrate nervous system. These molecules promote cell adhesion via a homophilic mechanism. These are not to be confused with ncam (neural cell adhesion molecule), now known to be expressed in a variety of tissues and cell types in addition to nervous tissue.
(12 Dec 1998)
cell adhesion molecules, neuron-glia Cell adhesion molecules that mediate neuron-neuron adhesion and neuron-astrocyte adhesion. They are expressed on neurons and schwann cells, but not astrocytes and are involved in neuronal migration, neurite fasciculation, and outgrowth. Ng-cam is immunologically and structurally distinct from ncam (neural cell adhesion molecules).
(12 Dec 1998)
cell aggregation The phenomenon by which dissociated cells intermixed in vitro tend to group themselves with cells of their own type.
(12 Dec 1998)
cell aging The decrease in the cell's ability to proliferate with the passing of time. Each cell is programmed for a certain number of cell divisions and at the end of that time proliferation halts. The cell enters a quiescent state after which it experiences cell death via the process of apoptosis.
(12 Dec 1998)
cell behaviour <cell biology> General term for activities of whole cells such as movement, adhesion and proliferation, by analogy with animal behaviour.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á